The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2025 | Improving evidence and understanding in localized digestive NECs
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, describes the limitations of current data on a localized digestive neuroendocrine carcinomas (NECs), highlighting the need for improved evidence, particularly given its low incidence. Enhancing the understanding of the disease’s biology and improving clinical study design are both necessary to better comprehend its underlying mechanisms. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Maybe it’s a problem because the data is not of high quality. I think that we need to improve our level of evidence. Most of the data coming from the registries or some retrospective data, multicenter, also some data from the population-based study. So because it’s a rare disease affecting 0.6 to 1 person per 100,000 people in different registries. So I think that for the future it is also important to better understand the biology and also improve the clinical design of the study in order to understand the biology of this disease better...
Maybe it’s a problem because the data is not of high quality. I think that we need to improve our level of evidence. Most of the data coming from the registries or some retrospective data, multicenter, also some data from the population-based study. So because it’s a rare disease affecting 0.6 to 1 person per 100,000 people in different registries. So I think that for the future it is also important to better understand the biology and also improve the clinical design of the study in order to understand the biology of this disease better.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
